University of Brescia, Brescia, Italy.
BJU Int. 2012 Apr;109(7):1013-8. doi: 10.1111/j.1464-410X.2011.10431.x. Epub 2011 Aug 24.
To compare the oncological outcomes of patients who underwent elective partial nephrectomy (PN) or radical nephrectomy (RN) for clinically organ-confined renal masses ≤7 cm in size (cT1).
The records of 3480 patients with cT1N0M0 disease were extracted from a multi-institutional database and analyzed retrospectively.
In patients who underwent PN, the risk of clinical understaging was 3.2% in cT1a cases and 10.6% in cT1b cases. With regard to the cT1a patients, the 5- and 10-year cancer-specific survival (CSS) estimates were 94.7% and 90.4%, respectively, after RN and 96.1% and 94.9%, respectively, after PN (log-rank test: P = 0.01). With regard to cT1b patients, the 5-year CSS probabilities were 92.6% after RN and 90% after PN, respectively (log-rank test: P = 0.89). Surgical treatment failed to be an independent predictor of CSS on multivariable analysis, both for cT1a and cT1b patients. Interestingly, PN was oncologically equivalent to RN also in patients with pT3a tumours (log-rank test: P = 0.91).
Elective PN is not associated with an increased risk of recurrence and cancer-specific mortality in both cT1a and cT1b tumours. Data from the present study strongly support the use of partial nephrectomy in patients with clinically T1 tumours, according to the current recommendations of the international guidelines.
比较行择期保留肾单位手术(PN)或根治性肾切除术(RN)治疗临床局限性肾肿瘤(cT1)大小≤7cm的患者的肿瘤学结果。
从一个多机构数据库中提取了 3480 例 cT1N0M0 疾病患者的记录,并进行回顾性分析。
在接受 PN 的患者中,cT1a 病例临床分期不足的风险为 3.2%,cT1b 病例为 10.6%。对于 cT1a 患者,RN 后 5 年和 10 年癌症特异性生存率(CSS)估计值分别为 94.7%和 90.4%,PN 后分别为 96.1%和 94.9%(对数秩检验:P=0.01)。对于 cT1b 患者,RN 后 5 年 CSS 概率分别为 92.6%和 90%(对数秩检验:P=0.89)。多变量分析显示,手术治疗不是 CSS 的独立预测因素,无论是 cT1a 还是 cT1b 患者。有趣的是,PN 在 pT3a 肿瘤患者中与 RN 一样具有肿瘤学等效性(对数秩检验:P=0.91)。
在 cT1a 和 cT1b 肿瘤中,选择性 PN 与复发和癌症特异性死亡率增加无关。本研究的数据强烈支持根据国际指南的当前建议,在临床上 T1 肿瘤患者中使用部分肾切除术。